Open access peer-reviewed Edited Volume

Cancer Targeted Immunotherapy in the Era of Precision Medicine

Hilal Arnouk

Midwestern University

An experienced researcher with a focus on Cancer Immunotherapy, Biomarker Discovery and Precision Medicine. He has received his education and post-doctorate training at Roswell Park Cancer Institute, the State University of New York at Buffalo, the Medical College of Georgia, and the University of Alabama at Birmingham, and is currently working as an Assistant Professor at the Department of Pathology at Midwestern University.

Covering

Targeted Cancer Therapy Biomarker Discovery Targeted Therapies Clinical Trials Immune Checkpoint Inhibitors Tumor Immune Evasion Combination Cancer Therapies Antibody Drug Conjugates (ADCs) Chimeric Antigen Receptors (CAR-T) Tumor-Infiltrating Lymphocytes (TILs) Immunotherapy Monitoring Biomarkers Graft vs. Tumor Effect Cell-Based Cancer Vaccines

Register your interest in contributing to this book

Collaborate with our community and contribute your knowledge.

About the book

Cancer targeted therapies, including cancer immunotherapy, are currently considered mainstream medical treatments for several types of malignancies. The success of these treatments relies on innovative approaches to specifically interfere with molecular targets that are involved in the growth, vascular and oxygen supply, progression, and spread of the malignant cells, or to bypass the tumor evasion of the immune system utilizing the latest advances in cancer vaccines development, formulation, and delivery.

This book will present an up-to-date overview of novel cancer targeted therapies and cancer personalized immunotherapy approaches, including Targeted Cancer Therapy, Biomarker Discovery, Targeted Therapies Clinical Trials, Molecular Medicine, Pharmacogenomics, Genomic Profiling, Oncolytic Viruses, Antibody Drug Conjugates (ADCs), Antibody-dependent cell-mediated cytotoxicity (ADCC), Monoclonal Antibodies, Bi-specific Antibodies, cGMP Antibody Manufacturing, Chimeric Antigen Receptors (CAR-T), Tumor-infiltrating lymphocytes (TILs), Adoptive T-cell Transfer, Cell-based Cancer Vaccines, Peptide-based Cancer Vaccines, Vaccine Delivery, Dendritic Cells, Natural Killer Cells, T-Lymphocytes, Tumor Antigens, Immunotherapy Monitoring Biomarkers, Graft vs. Tumor effect, Small-Molecule Drugs, Anti-Angiogenesis molecules, Hormonal Cancer Treatments, Combination Cancer Immunotherapy, and Cancer Immunotherapy Side Effects.

Publishing process

Book initiated and editor appointed

Date completed: September 24th 2020

Applications to edit the book are assessed and a suitable editor is selected, at which point the process begins.

Chapter proposals submitted and reviewed

Deadline for chapter proposals: October 22nd 2020

Potential authors submit chapter proposals ready for review by the academic editor and our publishing review team.

Register for the book

Approved chapters written in full and submitted

Deadline for full chapters: December 21st 2020

Once approved by the academic editor and publishing review team, chapters are written and submitted according to pre-agreed parameters

Full chapters peer reviewed

Review results due: March 11th 2021

Full chapter manuscripts are screened for plagiarism and undergo a Main Editor Peer Review. Results are sent to authors within 30 days of submission, with suggestions for rounds of revisions.

Book compiled, published and promoted

Expected publication date: May 10th 2021

All chapters are copy-checked and typesetted before being published. IntechOpen regularly submits its books to major databases for evaluation and coverage, including the Clarivate Analytics Book Citation Index in the Web of ScienceTM Core Collection. Other discipline-specific databases are also targeted, such as Web of Science's BIOSIS Previews.

About the editor

Hilal Arnouk

Midwestern University

Hilal Arnouk, MD, PhD is an Assistant Professor at the Department of Pathology at Midwestern University. Dr. Arnouk has received his education and post-doctorate training at Roswell Park Cancer Institute, the State University of New York at Buffalo, the Medical College of Georgia and the University of Alabama at Birmingham. He has directed research studies in academia and biotech industry settings. His major areas of expertise include Cancer Immunotherapy, Biomarker Discovery and Precision Medicine. Additionally, Dr. Arnouk tremendously enjoys being an educator for professional students in the medical and biomedical sciences.

View profile

Book chapters authored 1

Books edited 2

Introducing your Author Service Manager

Ms. Dajana Pemac

As an Author Service Manager my responsibilities include monitoring and facilitating all publishing activities for authors and editors. From chapter submission and review, to approval and revision, copyediting and design, until final publication, I work closely with authors and editors to ensure a simple and easy publishing process. I maintain constant and effective communication with authors, editors and reviewers, which allows for a level of personal support that enables contributors to fully commit and concentrate on the chapters they are writing, editing, or reviewing. I assist authors in the preparation of their full chapter submissions and track important deadlines and ensure they are met. I help to coordinate internal processes such as linguistic review, and monitor the technical aspects of the process. As an ASM I am also involved in the acquisition of editors. Whether that be identifying an exceptional author and proposing an editorship collaboration, or contacting researchers who would like the opportunity to work with IntechOpen, I establish and help manage author and editor acquisition and contact.

Ask a question
creativecommons
alpsp
cope
stm
ithenticate
crossref
doi
oaspa

Book will be abstracted and indexed in

googlescholar
worldcat
base
az
openaire